Attilizumab has been listed in China, but it can't be reimbursed by medical insurance at present. Attilizumab is marketed in China for non-small cell lung cancer. Attilizumab was developed by Roche Pharmaceutical Company of Switzerland. Because it was listed late in China, it has not been included in the medical insurance catalogue. In China, patients still need to buy this product at their own expense. The cost of imported drugs is relatively high, and the economic burden of patients is also relatively heavy.

Attilizumab is a commonly used anticancer drug in China in recent years, and many lung cancer patients need it. Due to the large gap in the purchase of atilizumab, patients do not intend to buy it, and many patients choose this product listed overseas. On the one hand, patients can go abroad to buy atilizumab, but it is a long way, risky and insecure. On the other hand, we can also obtain atilizumab listed overseas through domestic professional overseas medical service institutions, which can be guaranteed to be genuine and affordable, and can be delivered directly to home.

Atelizumab became the second PD-L 1 antibody to apply for listing in China after AstraZeneca Durvalumab. Attilizumab has been approved for the treatment of non-small cell lung cancer, triple-negative breast cancer and bladder cancer in the United States. Clinical trial results show that atilizumab (paclitaxel and carboplatin) combined with chemotherapy can significantly prolong the overall survival of patients with metastatic non-squamous non-small cell lung cancer without EGFR and ALK mutations. The median overall survival of the two groups is 65438 08.6 months VS 65438±03.9 months.

Attilizumab is an inhibitor of PD-L 1 and belongs to immunotherapy drugs. When patients with lung cancer and liver cancer choose to use atilizumab, doctors should judge whether to use it alone or in combination according to the tumor type and their own situation, so as to achieve the purpose of active and effective anti-cancer treatment.

Legal basis:

People's Republic of China (PRC) social insurance law

Twenty-third employees should participate in the basic medical insurance for employees, and employers and employees should pay the basic medical insurance premiums in accordance with state regulations. Individual industrial and commercial households without employees, part-time employees who have not participated in the basic medical insurance for employees and other flexible employees can participate in the basic medical insurance for employees, and individuals pay the basic medical insurance premium in accordance with state regulations.

Twenty-eighth medical expenses that meet the basic medical insurance drug list, diagnosis and treatment items, medical service facilities standards and emergency treatment and rescue shall be paid by the basic medical insurance fund in accordance with state regulations.